search
Back to results

Oral Cleft Prevention Trial in Brazil

Primary Purpose

Cleft Lip, Cleft Palate

Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Folic acid (0.4mg vs. 4.0mg)
Sponsored by
NICHD Global Network for Women's and Children's Health
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cleft Lip focused on measuring Cleft palate, Cleft lip, Folic acid, Global Network, Maternal and child health, International, Women's health, Brazil, Brasil, Latin America, ECLAMC, Congenital defects, Pregnancy

Eligibility Criteria

16 Years - 45 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: All women must reside in the state where the clinic is located. Women with NSCL/P who attend the craniofacial clinics, who are 16 to 45 years of age (after age 45 fecundity decreases substantially)who attend the craniofacial clinic for their care. Women (ages 16 to 45 years of age) who have at least one natural child of any age with NSCL/P who receives care at the participating craniofacial clinics. Exclusion Criteria: Cases resulting from consanguineous couples (first, second, and third degree, i.e., first cousins or closer). Couples where at least one of the two is definitely sterilized. Women on anti-epileptic drugs. Women who are pregnant. Women who are planning to move outside of the state where the clinic is located within the next year. Women who are planning to move outside of Sao Paulo state within the next year. Women who have B12 deficiency (B12 level is below 174 pg/ml or 134.328 pmol/L). Women who have an allergy to folic acid.

Sites / Locations

  • Hospital de Reabilitação de Anomalias Craniofaciais (HRAC)
  • Hospital de Clinicas de Porto Alegre (HCPA)
  • Hospital Santo Antonio-Centrinho: Obras Sociais Irma Dulce

Outcomes

Primary Outcome Measures

Recurrence of nonsyndromic cleft lip with or without cleft palate (NSCL/P) in offspring of trial mothers

Secondary Outcome Measures

Recurrence of NSCL/P compared to a historical control group; Overall and high versus low dose
Serum and red cell folate levels
Severity of NSCL/P in offspring of trial mothers
Twinning rate
Miscarriage rate
Preeclampsia
Rates of other birth defects
Birth weight
Gestational age

Full Information

First Posted
December 6, 2004
Last Updated
December 16, 2013
Sponsor
NICHD Global Network for Women's and Children's Health
Collaborators
Global Network for Women's and Children's Health Research, Bill and Melinda Gates Foundation, National Institute of Dental and Craniofacial Research (NIDCR), Fogarty International Center of the National Institute of Health, National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), RTI International, University of Iowa, Hospital de Reabilitação de Anomalias Craniofaciais (HRAC) - Brazil
search

1. Study Identification

Unique Protocol Identification Number
NCT00098319
Brief Title
Oral Cleft Prevention Trial in Brazil
Official Title
Oral Cleft Prevention Trial in Brazil
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NICHD Global Network for Women's and Children's Health
Collaborators
Global Network for Women's and Children's Health Research, Bill and Melinda Gates Foundation, National Institute of Dental and Craniofacial Research (NIDCR), Fogarty International Center of the National Institute of Health, National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), RTI International, University of Iowa, Hospital de Reabilitação de Anomalias Craniofaciais (HRAC) - Brazil

4. Oversight

5. Study Description

Brief Summary
Cleft lip and palate are a significant component of morbid human birth defects in the developing world. By supplementing a high-risk group of women with folic acid (4.0 mg versus 0.4 mg) from preconception and continuing throughout the first 3 months of pregnancy in the state of Sao Paulo, Brazil, this study aims to reduce the recurrence of cleft lip and palate.
Detailed Description
Craniofacial anomalies and cleft lip with or without cleft palate (CL/P) are a model for the impact of birth defects on fetal and neonatal health directly and maternal health indirectly. Craniofacial anomalies comprise a significant component of morbid human birth defects. The primary hypothesis is that folic acid supplementation of 4mg/day at preconception and during the first three months of pregnancy will decrease the recurrence of nonsyndromic cleft lip with or without clef palate (NSCL/P) in a high-risk group of women when compared to women taking 0.4 mg per day of folic acid. The total sample will include 2,000 women (that either have NSCL/P or that have at least one child with NSCL/P) randomly assigned to the 4 mg versus the 0.4 mg folic acid study groups. The study will also compare the recurrence rates of NSCL/P in the total sample of subjects as well as the two study groups (4mg, 0.4 mg) to that of a historical control group. The primary outcome assessed is the rate of recurrences of NSCL/P in offspring of the trial mothers in each of the two study groups. Secondary outcomes include recurrence of NSCL/P compared to a historical control group; serum and red cell folate levels; severity of NSCL/P in offspring of trial mothers; twinning rate; miscarriage rate; preeclampsia; rates of other birth defects; birth weight; and gestational age. The sample size was based on historic tables of birth rates and the rates of cleft occurrences. The study hypothesizes that a total of 2000 subjects will be enrolled during a 2.5 year period; a dropout rate of 10%; birth rate for group A (women with NSCL/P) of 10% and a rate of 12% for group B (women with at least one child with NSCL/P); risk of cleft for group A is 7% and for group B is 4%; one-sided test with continuity correction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cleft Lip, Cleft Palate
Keywords
Cleft palate, Cleft lip, Folic acid, Global Network, Maternal and child health, International, Women's health, Brazil, Brasil, Latin America, ECLAMC, Congenital defects, Pregnancy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
2200 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Folic acid (0.4mg vs. 4.0mg)
Primary Outcome Measure Information:
Title
Recurrence of nonsyndromic cleft lip with or without cleft palate (NSCL/P) in offspring of trial mothers
Secondary Outcome Measure Information:
Title
Recurrence of NSCL/P compared to a historical control group; Overall and high versus low dose
Title
Serum and red cell folate levels
Title
Severity of NSCL/P in offspring of trial mothers
Title
Twinning rate
Title
Miscarriage rate
Title
Preeclampsia
Title
Rates of other birth defects
Title
Birth weight
Title
Gestational age

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All women must reside in the state where the clinic is located. Women with NSCL/P who attend the craniofacial clinics, who are 16 to 45 years of age (after age 45 fecundity decreases substantially)who attend the craniofacial clinic for their care. Women (ages 16 to 45 years of age) who have at least one natural child of any age with NSCL/P who receives care at the participating craniofacial clinics. Exclusion Criteria: Cases resulting from consanguineous couples (first, second, and third degree, i.e., first cousins or closer). Couples where at least one of the two is definitely sterilized. Women on anti-epileptic drugs. Women who are pregnant. Women who are planning to move outside of the state where the clinic is located within the next year. Women who are planning to move outside of Sao Paulo state within the next year. Women who have B12 deficiency (B12 level is below 174 pg/ml or 134.328 pmol/L). Women who have an allergy to folic acid.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeff Murray, M.D.
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Reabilitação de Anomalias Craniofaciais (HRAC)
City
Bauru
State/Province
Sao Paulo
Country
Brazil
Facility Name
Hospital de Clinicas de Porto Alegre (HCPA)
City
Porto Alegre
Country
Brazil
Facility Name
Hospital Santo Antonio-Centrinho: Obras Sociais Irma Dulce
City
Salvador
Country
Brazil

12. IPD Sharing Statement

Links:
URL
http://gn.rti.org/
Description
Global Network for Women's and Children's Health Research
URL
http://www.rti.org/
Description
RTI International

Learn more about this trial

Oral Cleft Prevention Trial in Brazil

We'll reach out to this number within 24 hrs